Recently developed small molecule FSP1 inhibitors (see also chapter 3.6), including iFSP1 [51], FSEN1 [99], icFSP1 [100], and viFSP1 [101] sensitize a variety of cancer cell lines with different tissue origins and oncogenic driver mutations to ferroptosis. Here, AIFM2 is linked to cancer.